Practice Guidelines in Oncology for Rectal Cancer recommendations for the management of potentially resectable synchronous metastatic disease Describe the role of chemotherapy with bevacizumab in the conversion of CRLM to resectable status Case
Search Results
Hans F. Schoellhammer, Gagandeep Singh, and Lucille Leong
or metastatic disease that progresses following initial therapy with 5-FU/leucovorin plus bevacizumab. The following parameters were added for reporting of pathologic stage: lymphovascular invasion, perineural invasion, and extra nodal tumor
Andrew H. Ko and Margaret A. Tempero
: 131 – 138 . 55 Kindler HL Friberg G Stadler WM . Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial (Abstr) . In: Proceedings of the American Society
F. Anthony Greco
cancer of unknown primary: from autopsy to microarray . Eur J Cancer 2007 ; 43 : 2026 – 2036 . 3. Hurwitz H Fehrenbacher L Novotny W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J
Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen
provided in Table 2 . The most common combination was a fluoropyrimidine plus oxaliplatin with or without bevacizumab (37% and 33%, respectively). The remaining patients either received fluoropyrimidine/irinotecan or single-agent fluoropyrimidine
Lirong Liu, Fangfang Hou, Yufeng Liu, Wenzhu Li, and Haibo Zhang
hypermetabolic nodules in left hilar suggestive of lung cancer with obstructive pneumonia and bone and right adrenal metastases. (B1–B3) CT after 2 cycles of carboplatin/pemetrexed with bevacizumab shows left lower lobe atelectasis aggravated with a large
Philip J. Saylor and M. Dror Michaelson
trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer . N Engl J Med 2003 ; 349 : 427 – 434 . 7 Yang JC Sherry RM Steinberg SM . Randomized study of high-dose and low-dose interleukin-2 in
Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque
categories based on the reason for discordance, including (1) therapy mismatched with hormone receptor (HR) or HER2 status, (2) HER2-targeted therapy without chemotherapy, (3) nonapproved bevacizumab use, (4) adjuvant regimens received in the metastatic
Aparna Parikh, Chloe Atreya, W. Michael Korn, and Alan P. Venook
with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline. Next-generation sequencing (NGS) of the primary tumor identified HER2 amplification and we were able to obtain trastuzumab-DM1 for off-label use
Himani Aggarwal, Kristin M. Sheffield, Li Li, David Lenis, Rachael Sorg, and Rebecca Miksad
Background: PTL is a prognostic factor for mCRC. Recent data suggest PTL is also predictive of survival benefit with cetuximab (CET) and bevacizumab (BEV). This study evaluated the prognostic and predictive effect of PTL in patients with KRAS WT
